Printer Friendly

New CLSI Guideline Provides Protocols for Verification and Validation of Multiplex Nucleic Acid Assays.

WAYNE, Pa. -- Multiplex assays detect the presence of and discriminate two or more analytes simultaneously in the same sample. The number of commercially available multiplex assays is increasing rapidly, as is the number of laboratory-developed multiplex assays, and these use a variety of technologies and instrument platforms. Multiplex testing provides significant challenges to the laboratory with regards to appropriate verification and validation testing, and especially the acquisition of appropriate control and reference materials to conduct the testing.

Clinical and Laboratory Standards Institute (CLSI) has recently published a new document, Verification and Validation of Multiplex Nucleic Acid Assays; Proposed Guideline (MM17-P), which provides recommendations for analytic verification and validation of multiplex assays, as well as a review of different types of biologic and synthetic reference materials.

Topics covered in the guideline include:

* sample preparation;

* a general discussion of multiplex methods and technologies;

* reference and quality control materials;

* analytic verification and validation;

* data analysis; and

* reporting of results.

An overview of currently available technologies, as well as recommendations for evaluating new ones, is provided. An extensive review of the design, acquisition, and appropriate use of different types of control materials, including blood samples, residual patient samples, products of whole genome amplification, synthetic oligonucleotide simplex and multiplex controls, and plasmids, is provided. Current assay formats are used to illustrate proper verification and validation protocols, and appropriate data analysis and result reporting for multiplex assays are described.

The overall intent of this guideline is to assist laboratories and manufacturers in developing, verifying, validating, and implementing multiplex nucleic acid tests for diagnostic use.

For additional information on CLSI or for further information regarding this release, visit our website at http://www.clsi.org or call 610.688.0100.

CLSI, formerly NCCLS, is a global, nonprofit, membership-based organization dedicated to developing standards and guidelines for the healthcare and medical testing community. CLSI's unique consensus process facilitates the creation of standards and guidelines that are reliable, practical, and achievable for an effective quality system.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 14, 2007
Words:327
Previous Article:Gulf Ethanol Completes Site Selection for Ethanol Production Plant.
Next Article:Qiao Xing Mobile's Subsidiary, CECT, Launches Innovative Wrist Watch Mobile Phone.


Related Articles
Apply new nucleic acid-based technologies to detection.
Simplified sensor technology advances to commercialization.
QIAGEN LAUNCHES PRODUCT PORTFOLIO FOR RNAI/SYBR RT-PCR.
Motivating students to write about art.
"The List" a warrant service strategy.
Develop quantitative NASBA assay to detect E. coli.
QIAGEN UNVEILS FAST CYCLING PCR TECHNOLOGY.
Seven suggestions for IRS estate/gift tax audits.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters